Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01611142
Other study ID # PROTOCOL 0761-007
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2012
Est. completion date May 2015

Study information

Verified date June 2024
Source Kyowa Kirin Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4. CCR4 is the receptor for macrophage derived chemokines MDC/CCL22 and TARC/CCL17. Chemokines are considered to play a role both in the recruitment of immune and inflammatory cells for anti-tumor response and in the selective homing of neoplastic B and T cells.


Description:

PTCL is a rare and heterogeneous disease that remains difficult to diagnose and treat. In the majority of PTCL subtypes, patients are of older age (>60 years) and present with advanced stage disease.With the exception of the ALCL-ALK-positive subtype that responds well to CHOP combined chemotherapy, most PTCL subtypes become refractory even to aggressive chemotherapy regimens or relapse. Overall survival of PTCL patients is poor compared with that of aggressive B-cell lymphomas.Thus, novel and effective therapies are needed.KW-0761(mogamulizumab) is a defucosylated, humanized, IgG1 mAb with enhanced antibody dependent cellular cytotoxicity (ADCC)that binds to CCR4, a molecule that is suggested to be significantly involved in patients with PTCL.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years of age at the time of enrollment; 2. Histologically confirmed diagnosis of PTCL as specified below: - PTCL-NOS - Angioimmunoblastic T-cell lymphoma - Anaplastic large cell lymphoma, ALK-positive - Anaplastic large cell lymphoma, ALK-negative - Transformed mycosis fungoides 3. Failed or intolerant of at least one prior systemic anticancer therapy; 4. ECOG performance status score of = 2 at study entry; 5. At least one site of disease measurable in two dimensions by computed tomography (CT); 6. Subjects who are positive for CCR4 by immunohistochemistry; 7. Resolution of all clinically significant toxic effects of prior cancer therapy to grade =1 (NCI-CTCAE, v.4.0); 8. Adequate hematological hepatic and renal function. Exclusion Criteria: 1. Subject with the following PTCL diagnoses are excluded; - Precursor T/NK neoplasms - Adult T-cell leukemia-lymphoma - T-cell prolymphocytic leukemia - T-cell large granular lymphocytic leukemia - Aggressive NK-cell leukemia - Systemic EBV-positive T-cell lymphoproliferative disorder of childhood - Hydroa vacciniforme-like lymphoma - Mycosis fungoides, other than transformed mycosis fungoides - Sezary Syndrome - Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphatoid papulosis - Primary cutaneous CD8+ aggressive epidermotropic cytoxic T-cell lymphoma - Primary cutaneous CD4+ small/medium T-cell lymphoma - Primary cutaneous gamma-delta T-cell lymphoma - Extranodal NK/T T-cell lymphoma-nasal type - Enteropathy-associated T-cell lymphoma - Hepatosplenic T-cell lymphoma - Subcutaneous panniculitis -like T-cell lymphoma - Chronic lymphoproliferative disorder of NK cells 2. Have had an invasive solid tumor malignancy in the past five years except non-melanoma skin cancers, melanoma in situ, cervical carcinoma in situ, ductal/lobular carcinoma in situ of the breast, or localized prostate cancer with a current PSA of = 0.1 ng/ml who is currently without evidence of disease; 3. Relapsed less than 75 days of autologous stem cell transplant; 4. History of allogeneic stem cell transplant; 5. Evidence of central nervous system (CNS) metastasis; 6. Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements; 7. Subjects with a history of moderate or severe psoriasis or with psoriasis associated with systemic symptoms e.g. arthropathy), or with a 1st degree relative with history of psoriasis that required medical intervention; 8. Significant uncontrolled intercurrent illness; 9. Known or tests positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C; 10. Active herpes simplex or herpes zoster; 11. Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins; 12. Known active autoimmune disease will be excluded (For example: Grave's disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease); 13. Is pregnant (confirmed by beta human chorionic gonadotrophin [ß-HCG]) or lactating; Prohibited Therapies and/or Medications 14. Prior treatment with KW-0761; 15. Initiation of treatment with systemic steroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects; 16. Initiation of treatment with topical steroids while on study is not permitted except to treat an acute rash; 17. Have had anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational medications within 4 weeks of screening visit; 18. Subjects on any immunomodulatory drug.

Study Design


Intervention

Biological:
KW-0761 (mogamulizumab)
1 mg/kg administered intravenously weekly x 4 then every other week until progression

Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus
France CHU Henri Mondor Créteil Cedex
France CHRU Lille Lille Cedex
France Hopital Saint-Louis Paris
France Centre Hospitaliser de Lyon Sud Pierre Benite
France Centre Henri Becquerel Rouen
Italy Università di Bologna Bologna
Netherlands Vrije Universiteit Medisch Centrum (VUMC) Amsterdam
Netherlands Universitair Medisch Centrum Groningen (UMCG) Groningen
Spain Institut Catalá D'Oncologia, Hospital Duran y Reynals Barcelona
Spain Hospital Univesitario 12 de Octubre Madrid
Spain Hospital Clínico Universitario de Salamanca Salamanca
United Kingdom Guy's Hospital London
United Kingdom Christie Hospital Manchester
United Kingdom Cancer Research UK Centre/Southhampton General Hospital SouthHampton

Sponsors (2)

Lead Sponsor Collaborator
Kyowa Kirin Co., Ltd. Kyowa Hakko Kirin Pharma, Inc.

Countries where clinical trial is conducted

Denmark,  France,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate every 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT02445404 - Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL Phase 2
Completed NCT02168140 - CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Phase 1
Terminated NCT01644253 - Phase 1b Safety and Efficacy Study of TRU-016 Phase 1
Completed NCT01689220 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea Phase 1
Completed NCT01427881 - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Phase 2
Completed NCT01435863 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Phase 1
Terminated NCT00441025 - The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04312841 - Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Phase 2
Recruiting NCT04040491 - PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Phase 4
Terminated NCT01678443 - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT02142530 - Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Phase 1
Completed NCT02264613 - ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Completed NCT00131937 - Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Phase 2
Completed NCT00791947 - A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Phase 2
Recruiting NCT04880746 - Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study Phase 3